Mecasermin
From Wikipedia, the free encyclopedia
| Clinical data | |
|---|---|
| AHFS/Drugs.com | monograph |
| Pregnancy cat. | C (US) |
| Legal status | ℞-only (US) |
| Routes | Subcutaneous |
| Identifiers | |
| ATC code | H01AC03 |
| DrugBank | DB01277 |
| UNII | 7GR9I2683O  |
| KEGG | D04870  |
| ChEMBL | CHEMBL1201716 |
| Chemical data | |
| Formula | ? |
 (what is this?) (verify) |
|
Mecasermin (INN, brand name Increlex) is recombinant human insulin-like growth factor 1 (IGF-I) which is used for the long-term treatment of growth failure in children with severe primary IGF-I deficiency.[1][2]
This drug is not to be confused with mecasermin rinfabate (trade name: Iplex), which is the binary complex of recombinant human IGF-1 (rhIGF-1) and the binding protein that IGF-1 is naturally adhered to in the human body.
[edit] References
- ^ Fintini, D; Brufani, C; Cappa, M (2009). "Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency". Therapeutics and clinical risk management 5 (3): 553–9. PMC 2724186. PMID 19707272. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2724186.
- ^ "Increlex". Drugs.com. http://www.drugs.com/increlex.html. Retrieved 10 January 2010.
|
||||||||||||||||||||||||||||||||||
 |
This hormonal preparation article is a stub. You can help Wikipedia by expanding it. |
